Status of surgical treatment in recurrent and metastatic gastrointestinal stromal tumors        SHI Ying-qiang, Department of Abdominal Surgery, Cancer Hospital, Fudan University, Shanghai 200032, China
Abstract    Surgical treatment is still first choice in primary and local gastrointestinal stromal tumors (GIST). Imatinib was applied in the treatment of GIST patients. How to choose surgical treatment or targeted drug and how to select the combination of the two treatment options in patients with a huge or multiple mass and recurrent and metastatic GIST patients are still controversial, which need further investigation. Amount of bleeding during operation may be much more in GIST patients who choose targeted drug treatment in advance because the blood coagulation function of GIST patients might be affected by imatinib. Therefore, it is necessary to halt the drug and improve the blood coagulation function of GIST patients before operation.